MaxCyte Stock (NASDAQ:MXCT)
Previous Close
$2.25
52W Range
$2.00 - $5.20
50D Avg
$2.22
200D Avg
$3.26
Market Cap
$240.28M
Avg Vol (3M)
$876.94K
Beta
0.25
Div Yield
-
MXCT Company Profile
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.